Steven Mah
Stock Analyst at TD Cowen
(2.21)
# 2,821
Out of 5,135 analysts
29
Total ratings
37.93%
Success rate
11.08%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $54.92 | +5.61% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $22.84 | +35.73% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $8.95 | +1,240.78% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $3.53 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $11.81 | +255.63% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $3.13 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.71 | +484.80% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.70 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $1.17 | +1,694.87% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $215.53 | -28.08% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $23.34 | +499.83% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.63 | +3,090.18% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $120.09 | +245.57% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $24.16 | +934.77% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $54.92
Upside: +5.61%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $22.84
Upside: +35.73%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $8.95
Upside: +1,240.78%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $3.53
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $11.81
Upside: +255.63%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.13
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.71
Upside: +484.80%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.70
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $1.17
Upside: +1,694.87%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $215.53
Upside: -28.08%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $23.34
Upside: +499.83%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.63
Upside: +3,090.18%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $120.09
Upside: +245.57%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $24.16
Upside: +934.77%